CSL
News/ News/ Sales and Marketing
Australia’s CSL makes $11.7bn bid for Swiss pharma Vifor
Phil Taylor
CSL, CSL Behring, iron deficiency, M&A, nephrology, Seqirus, Vifor Pharma
0 Comment
News/ News/ News/ R&D/ Sales and Marketing
After Celgene deal, BMS shoots up pharma market cap rankings
Phil Taylor
AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, CSL, Daiichi Sankyo, Eli Lilly, Gilead Sciences, GlaxoSmithKline, GlobalData, Johnson & Johnson, M&A, Merck & Co, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, Vertex
0 Comment
Australia’s CSL on the rise as profits increase 30%
Richard Staines
CSL, results
0 Comment
US operations pull in revenues